CLINICAL TRIALS PROFILE FOR TALSACLIDINE
✉ Email this page to a colleague
Clinical Trials for Talsaclidine
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02248116 ↗ | Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type | Terminated | Boehringer Ingelheim | Phase 2/Phase 3 | Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK) |
| NCT02249351 ↗ | Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type | Terminated | Boehringer Ingelheim | Phase 2 | Study to assess symptomatic efficacy, safety and tolerability of talsaclidine in patients with mild to moderate dementia of Alzheimer type |
| NCT02249403 ↗ | Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type | Completed | Boehringer Ingelheim | Phase 2 | The objective of this trial was to assess the dose-response relationship of symptomatic efficacy of talsaclidine base on ADAScog and to assess safety and tolerability |
| NCT02264054 ↗ | Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects | Completed | Boehringer Ingelheim | Phase 1 | Study to investigate metabolism, pharmacokinetic, safety and tolerability of talsaclidine. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Talsaclidine
Condition Name
Clinical Trial Progress for Talsaclidine
Clinical Trial Phase
Clinical Trial Sponsors for Talsaclidine
Sponsor Name
